Abcam, ab308188, Anti-Influenza A virus PB1 protein antibody [HL1714]

Size: 100µL
Rabbit Recombinant Monoclonal Influenza A virus PB1 protein antibody. Carrier free. Suitable for ICC/IF, WB and reacts with Transfected cell line - Influenza A samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:HL1714,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Influenza A,
Applications:WB, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.

Product details:
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Influenza A PB1 protein also known as polymerase basic protein 1 forms a core part of the viral polymerase complex. It is a large protein with a molecular weight of approximately 85 kDa. PB1 expresses predominantly in the host cell cytoplasm and nucleus following an Influenza A virus infection. This protein orchestrates the replication and transcription of the viral RNA genome by taking part in the assembly of the viral RNA-dependent RNA polymerase. PB1 interacts with other subunits including PB2 and PA to form this essential polymerase complex.
Biological function summary
This viral protein facilitates the copying of viral RNA into progeny genomes and viral mRNA transcripts for protein synthesis. The PB1 component of the polymerase complex incorporates both the template-moving catalytic activities and binding sites. The functional partnerships between PB1 PB2 and PA bring the necessary enzymatic activities for efficient viral gene expression. Its role in the context of the polymerase complex makes it an important factor for the continuation of the viral life cycle ensuring efficient replication of the virus within the host.
Pathways
PB1 is vital to the viral replication pathway in that it interacts with other polymerase basic proteins like PB2 and related accessory proteins. This pathway oversees the synthesis of viral RNA in both transcriptional and replicative formats. It is closely related to the nuclear export by functioning with the PA and PB2 in the transport of new virus genomes and associated proteins to the host cell cytoplasm eventually leading to the assembly and release of infectious virions.
Influenza A PB1 contributes critically to the pathogenicity and spread of influenza infections in humans and animals. It is notably associated with seasonal flu outbreaks and pandemics. The PB1 protein's interactions with other surface proteins like HA (hemagglutinin) and NA (neuraminidase) influence virulence and transmissibility. Mutations in PB1 can alter the severity and outcome of flu infections making it a target for antiviral drug development and vaccine design aimed at mitigating the impact of influenza-induced respiratory illnesses and complications.